Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant
Open Access
- 22 July 2024
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107281
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The evolution of SARS-CoV-2Nature Reviews Microbiology, 2023
- Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trialThe Lancet Infectious Diseases, 2022
- Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discoveryComputers in Biology and Medicine, 2021
- Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018Antiviral Research, 2020
- Extensive diversity of coronaviruses in bats from ChinaVirology, 2017
- ModelFinder: fast model selection for accurate phylogenetic estimatesNature Methods, 2017
- Detecting and Analyzing Genetic Recombination Using RDP42016
- MEGAHIT v1.0: A fast and scalable metagenome assembler driven by advanced methodologies and community practicesMethods, 2016
- Genotype shift in human coronavirus OC43 and emergence of a novel genotype by natural recombinationJournal of Infection, 2015
- Fast and sensitive protein alignment using DIAMONDNature Methods, 2014